Durect News

H.C. Wainwright Maintains Durect(DRRX.US) With Hold Rating

H.C. Wainwright analyst Ed Arce maintains $Durect(DRRX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 39.3% and a total average return of 8.6% over the past year

moomoo NewsMay 23 05:34 ET

Northland Securities Maintains Durect(DRRX.US) With Buy Rating, Maintains Target Price $8.5

Northland Securities analyst Carl Byrnes maintains $Durect(DRRX.US)$ with a buy rating, and maintains the target price at $8.5.According to TipRanks data, the analyst has a success rate of 37.0% and a

moomoo NewsMay 23 01:31 ET

Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)

TipRanksMay 22 09:00 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersRezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago

BenzingaMay 21 16:31 ET

Express News | Hearing Oppenheimer Reiterates Outperform And $5 PT On DURECT

BenzingaMay 21 14:52 ET

Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon

Health care stocks were edging up Tuesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I

MT NewswiresMay 21 13:55 ET

DURECT Gets FDA Breakthrough Therapy Status for Larsucosterol

Seeking AlphaMay 21 10:10 ET

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. Durect (NASDAQ:DRR

BenzingaMay 21 08:06 ET

Express News | DURECT Corp -DURECT Plans to Confirm Efficacy and Safety of Larsucosterol in a Registrational Phase 3 Clinical Trial

ReutersMay 21 08:04 ET

Express News | DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

ReutersMay 21 08:00 ET

Express News | HC Wainwright & Co. Reiterates Neutral on Durect

BenzingaMay 15 10:53 ET

Durect Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 — HC Wainwright & Co. Reiterates → Neutral 04/01/2024 449.39% Oppenheimer → $5 Reiterates Outp

BenzingaMay 15 10:51 ET

Durect | 10-Q: Quarterly report

SEC announcementMay 14 16:45 ET · Announcements

Express News | DURECT Shares Are Trading Lower After the Company Reported a Year-over-year Decrease in Q1 Revenue Results

BenzingaMay 14 13:59 ET

Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says

Durect (DRRX) is not yet an earnings story but recent feedback from the US Food and Drug Administration is encouraging over its support for the advancement of larsucosterol into a single late-stage tr

MT NewswiresMay 14 13:21 ET

Cutera, Inotiv, Treace Medical Concepts Among Healthcare Movers

Seeking AlphaMay 14 10:00 ET

Durect (DRRX) Gets a Buy From Oppenheimer

TipRanksMay 14 07:56 ET

Durect (DRRX) Receives a Hold From H.C. Wainwright

TipRanksMay 14 06:32 ET

Durect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...

Yahoo FinanceMay 14 03:03 ET

Earnings Call Summary | Durect(DRRX.US) Q1 2024 Earnings Conference

The following is a summary of the DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript:Financial Performance:DURECT Corporation reported a decline in revenue from $2.1 million in 2023 to $1.8 mi

moomoo AIMay 14 00:16 ET · Conference Call